Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 16, 2026
Reporting period
Not applicable
Filed with the SEC
Aug 18, 2026
CEOIndirect holdingGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001493152-26-039048
Filed / recorded
Aug 18, 2026, 9:25 PM UTC
Added to OQRO
Oct 8, 2026, 2:51 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Dermata Therapeutics, Inc.
Issuer CIK
1853816
Ticker
DRMA
Reporting person
Gerald T Proehl
Relationship
Director, Officer, 10% owner
Officer title
PRESIDENT, CHAIRMAN, CEO
Security
Series E Warrant (Right to Buy)
Table
Derivative (Table II)
Transaction date
Aug 16, 2026
Transaction code
A
Shares / units
170,068
Acquired / disposed
Acquired (A)
Shares owned after
170,068
Ownership form
Indirect — By Sean Michael Proehl 2020 Irrevocable Trust Dated December 18, 2020
Amendment
No
Footnotes from the filing
The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock (or pre-funded warrant in lieu thereof) was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock.
The purchase price per share of common stock and accompanying warrants was $1.47 and the purchase price of each pre-funded warrant and accompanying warrants was $1.469.
This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common stock issuable upon exercise of the warrants. The warrant will expire five years from the effective date of stockholder approval. The warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.